Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Introduction
Shattuck Labs, Inc. is a clinical-stage biotechnology company that is pioneering the development of dual-action fusion proteins, a new class of biologic medicines. Utilizing their proprietary Agonist Redirected Checkpoint (ARC®) platform, the company is dedicated to designing bi-functional fusion proteins capable of simultaneously inhibiting immune checkpoints and activating costimulatory pathways. This approach is instrumental in reactivating anti-tumor immune responses and modulating autoimmune mechanisms, addressing significant unmet needs in oncology and autoimmune disorders.
Innovative Technology and Platform
The core of Shattuck Labs’ innovation lies in its proprietary ARC® platform, which enables the rational design of fusion proteins with a dual mechanism of action. By targeting key immune checkpoints such as CD47 and PD-1 while concurrently stimulating costimulatory receptors like CD40 and OX40, the company is able to enhance the efficacy of immune-mediated treatments without the need for multiple separate therapies. This strategic integration of inhibitory and agonistic functions within a single molecule sets the company apart in the competitive biotechnology landscape.
Product Pipeline and Clinical Programs
Shattuck Labs is actively advancing several clinical programs with its innovative fusion protein candidates:
- SL-172154 (SIRPα-Fc-CD40L): Designed to block inhibitory checkpoints and stimulate immune activation, this candidate is undergoing early-phase clinical evaluation to address advanced cancer indications.
- SL-279252 (PD1-Fc-OX40L): Developed in collaboration with a major pharmaceutical partner, this compound exemplifies the company’s commitment to designing fusion proteins that combine checkpoint inhibition with costimulatory activation.
- Gamma Delta T Cell Engager Platform: Known as gadlen™, this innovative approach aims to bridge gamma delta T cells to tumor antigens, thereby enhancing the immune system’s ability to target and destroy cancer cells.
Throughout these programs, Shattuck Labs maintains a balanced focus on therapeutic innovation, clinical safety, and efficacy, which is thoroughly reflected in their robust preclinical data and ongoing Phase 1 clinical studies.
Market Position and Competitive Landscape
In the dynamic field of biotechnology, Shattuck Labs has carved out a unique niche by leveraging advanced protein engineering and novel therapeutic strategies. The company’s dual-action approach not only positions it as an innovator in the development of biologic medicines but also enables it to address complex diseases with limited treatment options. With clinical programs targeting both hematologic malignancies and autoimmune conditions, Shattuck Labs stands as a significant contributor in the realm of precision immunotherapy and therapeutic innovation.
Expertise, Experience, and Corporate Profile
With offices located in Austin, Texas and Durham, North Carolina, Shattuck Labs benefits from a strong foundation in regional biotech hubs known for their robust research and development ecosystems. The company’s leadership and scientific teams bring extensive expertise in protein engineering, immuno-oncology, and drug development. Their work not only reflects a deep understanding of molecular biology and immune regulation but also underscores a disciplined approach to clinical development that is critical for advancing novel therapeutics safely and effectively.
Understanding the Bi-Functional Fusion Protein Approach
At the heart of Shattuck Labs’ operations is the concept of a bi-functional fusion protein – a therapeutic designed to perform two critical functions within one molecule. This innovative approach allows for:
- Simultaneous inactivation of inhibitory checkpoints that normally prevent an effective immune response.
- Activation of costimulatory pathways that enhance the body's ability to combat cancer cells or manage autoimmune responses.
This dual mechanism is a testament to the company’s expertise in synthesizing complex biological data and leveraging cutting-edge protein design to create more potent therapies with a potentially improved safety profile.
Conclusion
Shattuck Labs, Inc. represents a forward-thinking force in the biotechnology industry. By integrating innovative dual-action fusion proteins with state-of-the-art research and a well-structured clinical development program, the company continues to bolster its position as an informed and experienced player in the field of biologic medicine. Investors and industry stakeholders will find that the company not only addresses pressing medical challenges but also exemplifies a commitment to scientific rigor and therapeutic innovation.
Shattuck Labs (Nasdaq: STTK) reported Q2 2024 financial results and business highlights. Key points include:
1. Updated positive interim data from Phase 1B trial of SL-172154 with Azacitidine in HR-MDS and TP53m AML patients.
2. Enrollment ongoing in randomized Phase 1B dose-expansion cohort for frontline HR-MDS.
3. FDA granted Orphan Drug Designation for SL-172154 in AML treatment.
4. Q2 2024 financials: $105.3M cash and investments, $19.2M R&D expenses, $5.3M G&A expenses, $21.5M net loss ($0.42 per share).
5. Cash runway expected into 2026, beyond Phase 1 trial results for SL-172154.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotech company developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Dr. Taylor Schreiber, Shattuck's CEO, will engage in a fireside chat with BTIG analyst Kaveri Pohlman on August 5 at 2:00 p.m. ET. The company will also be available for one-on-one meetings during the conference. A live webcast of the fireside chat will be accessible to conference participants.
Shattuck Labs (Nasdaq: STTK), a clinical-stage biotechnology company focusing on bifunctional fusion proteins for cancer and autoimmune diseases, announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective July 1, 2024. This addition reflects the company's progress in advancing its lead candidate, SL-172154, in high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutated acute myeloid leukemia (TP53m AML). The annual Russell U.S. Indexes reconstitution includes the 4,000 largest U.S. stocks, ranking them by market capitalization. The Russell Indexes are widely used by investment managers and institutional investors for index funds and benchmarking active investment strategies.
Shattuck Labs has revealed updated positive interim data from the Phase 1B clinical trial of SL-172154 combined with Azacitidine (AZA) for treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML).
The trial showed a 67% objective response rate (ORR) in HR-MDS patients, with a 58% complete remission rate, while frontline TP53m AML patients exhibited a 43% ORR and 33% complete remission with incomplete hematologic recovery.
SL-172154 demonstrated a manageable safety profile, with the most common adverse events being infusion-related reactions. The median overall survival for both patient groups has not yet been reached.
Shattuck is focusing on HR-MDS and TP53m AML due to competition and potential for accelerated approval pathways. The company will host a conference call on June 14, 2024, to discuss these findings further.
Shattuck Labs announced that its lead clinical candidate, SL-172154, has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Acute Myeloid Leukemia (AML). This designation is awarded to drugs that address rare diseases affecting fewer than 200,000 people in the U.S. and provides benefits such as market exclusivity for seven years, tax credits for clinical trials, and waived application fees. The company plans to present additional data from the Phase 1B dose expansion clinical trial of SL-172154 at the European Hematology Association 2024 Congress.
Shattuck Labs will host an investor call and webcast on June 14, 2024, at 7:30 a.m. ET to discuss additional interim data from their Phase 1B dose expansion clinical trial of SL-172154 combined with Azacitidine (AZA) in treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The event, held during the European Hematology Association (EHA) 2024 Congress, will feature lead investigator Dr. Naval G. Daver from The University of Texas MD Anderson Cancer Center. The webcast will provide updates on safety and efficacy from the ongoing trial. Participants must register in advance to join the webcast, and a replay will be available for those unable to attend the live session.
Shattuck Labs (Nasdaq: STTK) will present new data from its Phase 1B trial of SL-172154 at the European Hematology Association (EHA) 2024 Congress. The trial, which combines SL-172154 with azacitidine (AZA), targets frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML). As of February 1, 2024, the combination therapy showed promising complete response (CR) rates and an acceptable safety profile. The HR-MDS cohort had a 65% objective response rate (ORR), while TP53m AML had a 36% ORR. The next data update is expected in the second quarter of 2024. Key safety concerns include infusion-related reactions and some severe treatment-emergent adverse events (TEAEs).
Shattuck Labs, Inc. (STTK) reported financial results for Q1 2024, highlighting progress in clinical trials for cancer treatments. They completed enrollment in Phase 1B cohorts for TP53m AML patients, presented preclinical data at AACR, and entered a collaboration with Ono Pharma. Financially, they have $114.6 million in cash and continue to focus on R&D.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is the core focus of Shattuck Labs, Inc.?
How does the ARC® platform work?
Which therapeutic areas does Shattuck Labs target?
What distinguishes Shattuck Labs from other biotech companies?
Can you elaborate on the company’s product pipeline?
Does Shattuck Labs collaborate with other companies?
